Why follow
Why reserve
Reasons to invest
Why follow us
Why reserve with us
Why invest in us
Here are the key reasons we believe our journey is worth following.
Here are the reasons we believe our company is worth considering as we prepare for a potential offering.
Here is why we believe our company and offering are worth considering.
Breath-Based Breast Cancer Screening
Maggie’s Breath is developing a point of care instrument that analyzes volatile organic compounds in a simple breath sample, to identify women who may have breast cancer
Advanced Sensing. Simple Breath.
BreathSense™ 1000 combines highly sensitive GC/SAW with diagnostic algorithms to analyze VOC patterns in breath and urine enabling painless rapid non-invasive screening that starts with a breath sample.
One Platform, Two Clinical Applications
Maggie’s Breath is investigating two complementary uses for breath-based VOC analysis: accessible breast cancer screening and support in distinguishing benign from malignant findings after suspicious breast imaging. Both pathways address distinct clinical needs and require validation
Team
Get to know us

William Wittmeyer
Founder and CEO

William “Bill” Wittmeyer is a technology entrepreneur with over 45 years of experience in engineering, venture capital, and commercializing innovative technologies.
A graduate of the U.S. Coast Guard Academy and Columbia University Business School, Bill is also President and CEO of Electronic Sensor Technology, a developer of advanced chemical detection systems.
Bill founded Maggies Breath with his late wife, Maggie Tham, to explore the potential of breath analysis to identify cancers. At Maggie’s insistence, the company focused its research on early breast cancer detection.
Tragically, Maggie passed away from breast cancer during the technology’s development.
Today, Bill is dedicated to building Maggie’s Breath as both a commercially successful medical diagnostics company and a lasting legacy to Maggie, advancing their shared vision of affordable, non-invasive cancer screening for women worldwide.

Rebecca Ottusch
Founder and Vice President Business Operations

Rebecca Ottusch is Co-Founder and Vice President of Business Operations at Maggie’s Breath, Inc., bringing experience in business development, real estate, sales, client relations, and communications.
With an entrepreneurial background and a talent for building relationships, Rebecca contributes to the company's business strategy, organizational development, investor communications, and strategic partnerships.
Her commitment to the Maggie’s Breath mission reflects a deeply personal dedication to improving breast cancer detection and expanding access to innovative diagnostic technologies.
Rebecca works alongside Co-Founder William B. Wittmeyer to advance the company's vision of developing affordable, accessible, and noninvasive breast cancer detection solutions.
The opportunity
What's our story
1
Transforming Breast Cancer Detection Through Breath Analysis
Our Vision
A future in which a simple breath sample can help make breast cancer detection more accessible, affordable, and convenient for women worldwide.
The Challenge
Breast cancer is one of the most frequently diagnosed cancers among women worldwide. Although mammography and other established diagnostic procedures save lives, many women encounter barriers involving cost, availability, geography, and access to timely follow-up care.
There is a compelling need for additional noninvasive technologies that could expand access to breast cancer detection.
Our Innovation
Maggie’s Breath is developing an investigational diagnostic technology that analyzes volatile organic compounds (VOCs) found in human breath.
The proposed system combines gas chromatography and surface acoustic wave (GC/SAW) sensing technology with advanced analytical algorithms designed to recognize chemical patterns potentially associated with breast cancer.
The company is also investigating the potential complementary use of urinary VOC analysis.
Our Development Strategy
Maggie’s Breath is pursuing two complementary research objectives:
Early Detection: Evaluate the potential of breath analysis as an accessible approach to breast cancer screening through proposed clinical research in India.
Diagnostic Support: Investigate whether VOC analysis can help distinguish benign from malignant findings in patients with suspicious breast imaging results through a proposed U.S. clinical study.
Both applications require clinical validation and appropriate regulatory review.
Our Business Opportunity
Maggie’s Breath envisions a scalable medical diagnostics business combining analytical instrumentation, disposable VOC collection devices, diagnostic algorithm services, and ongoing equipment support.
This proposed business model could generate equipment sales and recurring testing-related revenue, subject to successful clinical development, regulatory authorization, and market adoption.
Our Mission
Inspired by Maggie’s life and legacy, Maggie’s Breath is committed to advancing medical innovation that may help improve access to breast cancer detection and ultimately contribute to better outcomes for women.

About
About us
Headquarters
Thousand Oaks, CA
Industry
Healthcare & Life Sciences
Maggie’s Breath is developing an innovative, noninvasive technology for early breast cancer detection using a simple breath sample. By combining advanced gas chromatography, surface acoustic wave (GC/SAW) sensing, and diagnostic algorithms, the technology analyzes volatile organic compounds (VOCs) that may be associated with breast cancer. Our mission is to make breast cancer detection more accessible, affordable, and convenient for women worldwide.
Potential offering terms
Potential offering terms
Offering terms
What the company is considering
What the company is considering
The terms of this offering
These terms are preliminary and may change before any offering is launched. The company may also decide not to proceed with a raise.
These terms are preliminary and may change before any offering is launched. The company may also decide not to proceed with a raise.
These are the current terms of the live offering. Review the Form C and offering documents for complete details before investing.
Reservations are non-binding, require no payment method, and do not guarantee an investment. These potential terms may change before launch, and the company may decide not to proceed with an offering.
Reservations are non-binding, require no payment method, and do not guarantee an investment. These potential terms may change before launch, and the company may decide not to proceed with an offering.
The offering terms shown here summarize the current offering. The filed Form C and any amendments control if there is any difference.
Security details
Use of proceeds
Key risks
What investors should consider
These are illustrative highlights only. Review the Form C for the complete risk factors and disclosures.
Early-stage risk. The company may not achieve its business plan or may require additional capital.
Illiquidity. There may be no market for these securities, and resale is restricted.
Dilution. Future financings may reduce your ownership percentage or economic interest.
Loss of investment. You should be prepared to lose your entire investment.
Offering documents
Review before you invest
Read the filed offering materials and related documents before making an investment decision.
Investing in private companies is speculative and illiquid. You could lose your entire investment. Review the Form C, offering terms, risk factors, and offering documents before investing. EquityCF does not provide investment advice or recommend any offering.